Static Chart Kymera Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 20/04/2026 BST			5-day change	1st Jan Change
86.93 ^USD	-0.89%		+2.21%	+11.72%

04-13	Kymera Therapeutics Wins FDA Fast Track for Oral Asthma Drug	MT
04-13	Kymera Therapeutics, Inc. Announces U.S. FDA Fast Track Designation for KT-621, A First-In-Class, Oral Stat6 Degrader for the Treatment of Moderate to Severe Asthma	CI

Duration

Period